IMC-002
Phase 1Small molecule
IMC-002 is one of 105 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.
3
Indications
4
Total Trials
3
Active Trials
104
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Zofran
NovartisPreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
PEG-Intron
Merck & Co.Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
IMC-002
IImmuneOncia Therapeutics Inc.
Phase 1
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuromyelitis Optica1 trial
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
Not yet recruiting·IImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.·Phase 1/2·NCT06557174·116 enrolled
Advanced Cancer1 trial
Lymphoma1 trial
Systemic Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMC-002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- IImmuneOncia Therapeutics Inc.